Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The enhanced permeability and retention (EPR) effect has underlain the predominant nanomedicine design philosophy for the past three decades. However, growing evidence suggests that it is over-represented in preclinical models, and agents designed solely using its principle of passive accumulation can only be applied to a narrow subset of clinical tumors. For this reason, strategies that can improve upon the EPR effect to facilitate nanomedicine delivery to otherwise non-responsive tumors are required for broad clinical translation. EPR-adaptive nanomedicine delivery comprises a class of chemical and physical techniques that modify tumor accessibility in an effort to increase agent delivery and therapeutic effect. In the present review, we overview the primary benefits and limitations of radiation, ultrasound, hyperthermia, and photodynamic therapy as physical strategies for EPR-adaptive delivery to EPR-insensitive tumor phenotypes, and we reflect upon changes in the preclinical research pathway that should be implemented in order to optimally validate and develop these delivery strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 2×
“While these fall under the classification of EPR-adaptive delivery, they have been extensively reviewed elsewhere [7,20,39,40,41,42,43], and thus will not be the focus of this review.”
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“Reductions in pressure are due to a combination of factors, including vascular regression, death of tumor cells which compress microvasculature, and decreased resistance to blood flow [56,57].”
BackgroundDanhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262 · cited 2×
“While this may lead to a more powerful predictive tool for determining tumor phenotype, it also requires additional work to develop trackable components for each new therapeutic to be tested, likely in the form of a companion nanodiagnostic or an incorporable chelator for radiolabeling [39,131].”
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · cited 1×
“This unrealized potential has led to a questioning of the ubiquity of the EPR effect, including critiques by its founders [7,8].”
BackgroundChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 1×
“Hormonal effectors, such as the angiotensin II receptor antagonist losartan, can capitalize on these principles as well – in this case, its action decompresses tumor vessels, increases tumor perfusion, and suppresses collagen synthesis, leading to enhanced drug accumulation [36,37].”
BackgroundNichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 1×
“Hormonal effectors, such as the angiotensin II receptor antagonist losartan, can capitalize on these principles as well – in this case, its action decompresses tumor vessels, increases tumor perfusion, and suppresses collagen synthesis, leading to enhanced drug accumulation [36,37].”
BackgroundThe distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Orthotopic patient-derived xenografts of paediatric solid tumours
Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., et al. (2017) · Nature · doi:10.1038/nature23647 · Cited by 286 · cited 1×
“PDX allow for the transplantation of tumor cells directly from a patient into an animal model, often preserving stromal structures and allowing for testing against specific, low-incidence cancer phenotypes [140].”
BackgroundEikenes, L., Tari, M., Tufto, I., Bruland, Ø. S., & de Lange Davies, C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602626 · Cited by 221 · cited 1×
“Treatment with enzymes that digest the physical structure of the ECM, such as collagenase [29] and hyaluronidase [30,31,32,33], lower interstitial fluid pressure in tumors, while direct induction of apoptosis in cancer and stromal cells can reduce pressure on microvasculature to improve depth of penetration of agents…”
BackgroundNanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128 · cited 1×
“97) and were able to provide predictions for therapeutic outcome by stratifying mice into high and low accumulation subgroups (threshold of 25 mg/kg interpolated uptake at the tumor site), displaying categorical differences in relative tumor size increase and median survival [133].”
BackgroundLammers, T., Peschke, P., Kühnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., & Storm, G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.032 · Cited by 124 · cited 2×
“High rates of angiogenesis in xenografts lead to uniformly low pericyte coverage and large endothelial fenestrations [105,130], enhancing extravasation potential [134], while clinical counterparts have more heterogeneity in vessel leakiness, often comprising of both vasculature with complete pericyte coverage and vasc…”
BackgroundChen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Cited by
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Metadata
- Authors
- Dhaliwal, A., & Zheng, G.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 26
- Pages
- 8091-8108
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2982594171
- Cited by
- 103
- References
- 16
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.